Market News How it works Learn FAQ
| RCT 0.1382 81.60% | NU 11.97 -21.04% | TGL 0.2617 18.15% | EWZ 32.715 -23.19% | SRTM 0.3394 -21.12% | BBD 2.835 -30.34% | SHFS 0.0989 -25.30% | GCDT 0.1322 -24.93% | ITUB 7.368 -23.81% | NWGL 0.0817 -0.37% | CLRO 4.67 43.69% | XP 14.8623 -51.13% | AZTR 1.265 76.92% | RBNE 0.1664 -12.42% | PBR 21.535 -17.68% | SGRY 23.055 46.38% | SOXL 85.96 2.87% | TSLL 10.8899 11.58% | SPCX 147.535 0.03% | VALE 12.0045 -3.19% | SPRC 1.4499 33.02% | NVD 4.04 -3.58% | CRWV 54.96 1.34% | JBLU 2.2085 -15.87% | SOXS 51.01 -2.76% | INTC 87.29 0.38% | GPUS 0.1679 -0.59% | NVDA 215 1.92% | TSLA 394.1 5.88% | IREN 24.64 -1.06% | ABEV 2.7991 -15.18% | TQQQ 67.83 2.32% | RENT 2.9899 30.00% | NOK 8.46 3.93% | INTR 4.415 -38.60% | PBR-A 18.92 -19.59% | XTND 2.8083 58.66% | SQQQ 38.76 -2.32% | BITO 10.6402 -1.75% | LUCD 0.5437 32.29% | SPDN 8.495 -0.53% | VBIO 0.8098 -13.85% | SBS 4.765 -25.55% | XXII 0.0999 -49.47% | SID 0.9233 -21.75% | STNE 7.96 -30.66% | KORU 10.6 0.19% | WFF 0.0765 -4.38% | RWM 14.4501 -0.69% | TSLG 5.45 11.91%
RVRVL Pharmaceuticals plc logo

RVL Pharmaceuticals plc (RVLPQ)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+0.00%)
As of Oct 26, 9:30 AM ET. Market open.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $0.00
Volume
3,215
Avg. Volume
9,532
Market Cap
$314.17K
Beta (5Y Monthly)
8.80
PE Ratio (TTM)
--
EPS (TTM)
-$0.58
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: RVL Pharmaceuticals plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
125
CEO
Brian A. Markison

RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities extend across the United States, Argentina, and Hungary. Its principal commercial offering is Upneeq (RVL-1201), an ophthalmic solution containing oxymetazoline hydrochloride, specifically formulated to address acquired blepharoptosis, or drooping eyelids, in adults.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.24 · Revenue est. $30.65M
DateEst.Actual
Jun 30, 2023-$0.11-$0.24Miss

Get free alerts on RVLPQ and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.